Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMTMVEW)

Drug Name
JCAR014 Drug Info
Indication
Disease Entry ICD 11 Status REF
Non-hodgkin lymphoma 2B33.5 Phase 1/2 [1]
B-cell lymphoma 2A86 Phase 1 [2]
B-cell non-hodgkin lymphoma 2B33.5 Phase 1 [3]
Diffuse large B-cell lymphoma 2A81 Phase 1 [2]
Mediastinal large B-cell lymphoma 2A60.32 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMTMVEW

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
B-lymphocyte surface antigen B4 (CD19) DTT CD19 5.758 6.211 6.083 5.396
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-hodgkin lymphoma
ICD Disease Classification 2B33.5
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041075)
2 ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)